Specify Company / Ticker to Get the Summary
CohBar Inc
CWBRCohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California. Address: 1455 Adams Drive, Menlo Park, CA, United States, 94025
Analytics
WallStreet Target Price
18 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CWBR
Dividend Analytics CWBR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CWBR
Stock Valuation CWBR
Financials CWBR
Results | 2019 | Dynamics |